John Overdeck’s Genocea Biosciences, Inc. GNCA Stock Holding History

John Overdeck’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-57,836	Closed	-$111K	–	5153
2021 Q3	$111K	Sell	57,836 -96,611	-63%	-$190K	﹤0.01%	4074
2021 Q2	$361K	Sell	154,447 -234,562	-60%	-$565K	﹤0.01%	3358
2021 Q1	$1.05M	Buy	389,009 +39,765	+11%	+$118K	﹤0.01%	2265
2020 Q4	$845K	Buy	349,244 +167,234	+92%	+$381K	﹤0.01%	2130
2020 Q3	$417K	Buy	+182,010	New	+$478K	﹤0.01%	2371
2020 Q1	–	Sell	-21,938	Closed	-$45K	–	4146
2019 Q4	$45K	Buy	+21,938	New	+$52K	﹤0.01%	3574

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

John Overdeck's GNCA Position: Q4 2021 in Review

John Overdeck sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2021, closing a stake of 57,836 shares — an estimated $111K sold.

John Overdeck first reported a position in GNCA in Q4 2019 and held it in 6 quarters. The position peaked at $1.05M in Q1 2021. 41 funds tracked by Wall St. Rank hold GNCA as of Q4 2021.

John Overdeck reported no remaining Genocea Biosciences, Inc. position as of Q4 2021 after selling out during the quarter.
John Overdeck sold 57,836 Genocea Biosciences, Inc. shares in Q4 2021, an estimated $111K.
John Overdeck first reported a position in Genocea Biosciences, Inc. in Q4 2019 and held it in 6 quarters.
John Overdeck's Genocea Biosciences, Inc. position peaked at $1.05M in Q1 2021.
41 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2021.

Based on Two Sigma Investments's 13F filing for Q4 2021, filed 14 Feb 2022.